Letters to the Editor

FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)(DEK::NUP214): The Mayo Clinic experience

Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA; Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Haematologica Early view Jun 20, 2024 https://doi.org/10.3324/haematol.2024.285359